Natalia Leonidovna Ronzhina

Mrs. Natalia Leonidovna Ronzhina

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2015 in Electrophoresis
Verified
Journal Article
Open access
PDF file
Stanislav NaryzhnyStanislav Naryzhny
Stanislav Naryzhny
VZVictor Zgoda
Victor Zgoda
MMMaria A. Maynskova
Maria A. Maynskova
SNSvetlana Novikova
Svetlana Novikova
NRNatalia Leonidovna Ronzhina
Natalia Leonidovna Ronzhina
AAAlexander Archakov
Alexander Archakov
Virtual and experimental 2DE coupled with ESI LC‐MS/MS was introduced to obtain better representation of the information about human proteome. The proteins from HEPG2 cells and human blood plasma were run by 2DE. After staining and protein spot identification by MALDI‐TOF MS, the protein maps were generated. The experimental physicochemical parameters (pI/Mw) of the proteoforms further detected by ESI LC‐MS/MS in these spots were obtained. Next, the theoretical pI and Mw of identified proteins were calculated using program Compute pI/Mw (http://web.expasy.org/compute_pi/pi_tool‐doc.html). Accordingly, the relationship between theoretical and experimental parameters was analyzed, and the correlation plots were built. Additionally, virtual/experimental information about different protein species/proteoforms from the same genes was extracted. As it was revealed from the plots, the major proteoforms detected in HepG2 cell line have pI/Mw parameters similar to theoretical values. In opposite, the minor protein species have mainly very different from theoretical pI and Mw parameters. A similar situation was observed in plasma in much higher degree. It means that minor protein species are heavily modified in cell and even more in plasma proteome.

23 December 2015 in Journal of Proteome Research
Verified
Journal Article
Closed access
Stanislav NaryzhnyStanislav Naryzhny
Stanislav Naryzhny
MMMaria A. Maynskova
Maria A. Maynskova
VZVictor Zgoda
Victor Zgoda
NRNatalia Leonidovna Ronzhina
Natalia Leonidovna Ronzhina
OKOlga A. Kleyst
Olga A. Kleyst
AAAlexander Archakov
Alexander Archakov

Verified
Journal Article
Open access
PDF file
Stanislav NaryzhnyStanislav Naryzhny
Stanislav Naryzhny
NRNatalia Leonidovna Ronzhina
Natalia Leonidovna Ronzhina
EZElena Zorina
Elena Zorina
FKFedor Kabachenko
Fedor Kabachenko
MZMaria Zavialova
Maria Zavialova
RPRimma Pantina
Rimma Pantina
Haptoglobin (Hp) is a blood plasma glycoprotein that plays a critical role in tissue protection and the prevention of oxidative damage. Haptoglobin is an acute-phase protein, its concentration in plasma changes in pathology, and the test for its concentration is part of normal clinical practice. Haptoglobin is a conservative protein and is the subject of research as a potential biomarker of many diseases, including malignant neoplasms. The Human Hp gene is polymorphic and controls the synthesis of three major phenotypes—homozygous Hp1-1 and Hp2-2, and heterozygous Hp2-1, determined by a combination of allelic variants that are inherited. Numerous studies indicate that the phenotype of haptoglobin can be used to judge the individual’s predisposition to various diseases. In addition, Hp undergoes various post-translational modifications (PTMs). Glioblastoma multiform (GBM) is the most malignant primary brain tumor. In our study, we have analyzed the state of Hp proteoforms in plasma and cells using 1D (SDS-PAGE) and 2D electrophoresis (2DE) with the following mass spectrometry (LC ES-MS/MS) or Western blotting. We found that the levels of α2- and β-chain proteoforms are up-regulated in the plasma of GBM patients. An unprocessed form of Hp2-2 (PreHp2-2, zonulin) with unusual biophysical parameters (pI/Mw) was also detected in the plasma of GBM patients and glioblastoma cells. Altogether, this data shows the possibility to use proteoforms of haptoglobin as a potential GBM-specific plasma biomarker.

Verified
Journal Article
Open access
PDF file
Stanislav NaryzhnyStanislav Naryzhny
Stanislav Naryzhny
NRNatalia Leonidovna Ronzhina
Natalia Leonidovna Ronzhina
EZElena Zorina
Elena Zorina
FKFedor Kabachenko
Fedor Kabachenko
NKNikolay Klopov
Nikolay Klopov
VZVictor Zgoda
Victor Zgoda
The use of tumor markers aids in the early detection of cancer recurrence and prognosis. There is a hope that they might also be useful in screening tests for the early detection of cancer. Here, the question of finding ideal tumor markers, which should be sensitive, specific, and reliable, is an acute issue. Human plasma is one of the most popular samples as it is commonly collected in the clinic and provides noninvasive, rapid analysis for any type of disease including cancer. Many efforts have been applied in searching for “ideal” tumor markers, digging very deep into plasma proteomes. The situation in this area can be improved in two ways—by attempting to find an ideal single tumor marker or by generating panels of different markers. In both cases, proteomics certainly plays a major role. There is a line of evidence that the most abundant, so-called “classical plasma proteins”, may be used to generate a tumor biomarker profile. To be comprehensive these profiles should have information not only about protein levels but also proteoform distribution for each protein. Initially, the profile of these proteins in norm should be generated. In our work, we collected bibliographic information about the connection of cancers with levels of “classical plasma proteins”. Additionally, we presented the proteoform profiles (2DE patterns) of these proteins in norm generated by two-dimensional electrophoresis with mass spectrometry and immunodetection. As a next step, similar profiles representing protein perturbations in plasma produced in the case of different cancers will be generated. Additionally, based on this information, different test systems can be developed.

14 July 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
Stanislav NaryzhnyStanislav Naryzhny
Stanislav Naryzhny
NRNatalia Leonidovna Ronzhina
Natalia Leonidovna Ronzhina
EZElena Zorina
Elena Zorina
FKFedor Kabachenko
Fedor Kabachenko
NKNikolay Klopov
Nikolay Klopov
VZVictor Zgoda
Victor Zgoda
Cancer is a complex systemic disease that changes the entire proteome. The analysis of this transformation makes it possible to determine tumor markers, that is, the most characteristic biomacromolecules produced by tumor cells. Here, the question of finding ideal tumor markers, which should be sensitive, specific, and reliable, is an acute issue. Unfortunately, none of the tumor markers, even those used in the clinic, has all these characteristics. Despite this, many tumor markers have demonstrated excellent clinical relevance for monitoring the effectiveness of different treatments for cancer patients. The use of markers also aids in the early detection of cancer recurrence and prognosis. Therefore, the situation in this area can be improved in two ways – by attempting to find an ideal single tumor marker or generating panels of different markers. In both cases, proteomics certainly plays a major role. Human plasma is one of the most popular samples as it is commonly collected in the clinic and provides noninvasive, rapid analysis for any type of disease including cancer. Many efforts have been applied in searching for “ideal” tumor markers digging very deep plasma proteome. There is a line of evidence that the most abundant, so-called “classical plasma proteins”, may be used to generate a tumor biomarker profile. To be comprehensive these profiles should have information not only about protein levels but proteoform distribution for each protein. Initially, the profile of these proteins in norm should be generated. Here, we present data about these profiles generated by two-dimensional electrophoresis with the following mass-spectrometry and immunodetection.

1 July 2025 in Proteomes
Verified
Journal Article
Open access
PDF file
EZElena Zorina
Elena Zorina
NRNatalia Leonidovna Ronzhina
Natalia Leonidovna Ronzhina
OLOlga Legina
Olga Legina
NKNikolai Klopov
Nikolai Klopov
VZVictor Zgoda
Victor Zgoda
Stanislav NaryzhnyStanislav Naryzhny
Stanislav Naryzhny
Background: Human proteins exist in numerous modifications—proteoforms—which are promising targets for biomarker studies. In this study, we aimed to generate comparative proteomics data, including proteoform patterns, from hepatocellular carcinoma (HCC) and nonmalignant liver tissues. Methods: To investigate protein profiles and proteoform patterns, we employed a panoramic, integrative top-down proteomics approach: two-dimensional gel electrophoresis (2DE) coupled with liquid chromatography–electrospray ionization–tandem mass spectrometry (LC-ESI-MS/MS). Results: We visualized over 2500 proteoform patterns per sample type, enabling the identification of distinct protein signatures and common patterns differentiating nonmalignant and malignant liver cells. Among these, 1270 protein patterns were uniformly observed across all samples. Additionally, 38 proteins—including pyruvate kinase PKM (KPYM), annexin A2 (ANXA2), and others—exhibited pronounced differences in proteoform patterns between nonmalignant and malignant tissues. Conclusions: Most proteoform patterns of the same protein were highly similar, with the dominant peak corresponding to theoretical (unmodified) protein parameters. However, certain proteins displayed altered proteoform patterns and additional proteoforms in cancer compared to controls. These proteins were prioritized for further characterization.